# A Study Evaluating the Safety and Tolerability of QRL-201 in ALS

> **NCT05633459** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **QurAlis Corporation** · enrollment: 69 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Multiple ascending doses of QRL-201
- **DRUG:** Multiple ascending doses of Placebo
- **DRUG:** QRL-201
- **DRUG:** Placebo
- **DRUG:** QRL-201

## Key facts

- **NCT ID:** NCT05633459
- **Lead sponsor:** QurAlis Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-16
- **Primary completion:** 2026-05-29
- **Final completion:** 2027-11-30
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05633459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05633459, "A Study Evaluating the Safety and Tolerability of QRL-201 in ALS". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT05633459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*